Terrestrial Bio, Inc., a biotech company transforming the delivery of next-generation therapies, announced the opening of its new headquarters and manufacturing facility at 250 Western Avenue in Allston, Massachusetts, on October 30, 2026.

The company celebrated the milestone with a grand opening and ribbon-cutting ceremony on October 28, bringing together employees, government leaders, investors, and public and private partners.

Terrestrial Opens 40,000-Square-Foot Patch Manufacturing Facility

Located at Allston Labworks, the facility spans more than 40,000 square feet and is designed to support production of Terrestrial's Tacterra™ microarray patches for clinical trials and demonstration of commercial-scale production for its lead program, VX-201, delivering GLP-1.

The facility integrates automation, robotics, machine vision, and advanced analytics to help the company scale manufacturing and strengthen quality control as its therapeutic programs advance.

Massachusetts Economic Development Secretary Eric Paley and MLSC's Elizabeth Graham joined Terrestrial CEO Rachel Sha for the ribbon cutting, which celebrated the company's growing presence in the Bay State.

CEO Points to Patient Experience as Guiding Focus

"Imagine a future where you can stay healthy, feel and look the way you want, and live the life that you hope to live, with less daily struggle to access and afford transformative medication," said Rachel Sha, CEO of Terrestrial.

"At Terrestrial, we're grounded in the patient experience. We're focused on developing products that help improve patient lives… We are so excited to be here in our new headquarters, which will help us realize this future sooner."

The opening expands Terrestrial's presence in Massachusetts and establishes a foundation for long-term growth in the Commonwealth. By investing in advanced manufacturing capabilities at its headquarters, Terrestrial is laying the groundwork for a long-term manufacturing presence in Boston that creates high-quality jobs.

State Officials Celebrate Partnership

"Massachusetts is the most curious place on earth; it's a place where you are valued for the questions you ask… and uniquely valued for the quality of your questions," said Eric Paley, Secretary of the Massachusetts Executive Office of Economic Development.

"Questions might be 'What medicines might help people thrive?' … But another really important question is 'How do we make it the easiest possible way to access these medicines?'... We think that kind of curiosity in what Terrestrial has done here can ultimately change the world... We are here to support you in any way we can. We are delighted to be a part of what you're creating."

"It's a pleasure to be here today and see a tremendous partnership," said Elizabeth Graham, Interim President and CEO of the MLSC. "Terrestrial is really what makes the Commonwealth such an amazing place to be."

More Than USD 2.2 Million in State Grant Support

Terrestrial's manufacturing expansion has received support through two Massachusetts state grants totaling more than USD 2.2 million.

These include a USD 1.4 million BioBoost Award from the Massachusetts Life Sciences Center (MLSC) to support commercial-scale facility development and a USD 850,000 award through the Massachusetts Manufacturing Innovation Initiative (M2I2), administered by the Massachusetts Technology Collaborative's Center for Advanced Manufacturing.

Facility Opening Follows a Year of Milestones

The opening follows several milestones for Terrestrial in 2026. In March, the company announced a USD 50 million Series C financing.

In July, Terrestrial announced that it had dosed the first participants in a Phase 1 clinical trial evaluating VX-201, its investigational Tacterra™ microarray patch for semaglutide delivery.

About the Tacterra Platform

Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1. The company's proprietary Tacterra™ microarray patch (MAP) and applicator platform consists of a patch resembling an adhesive bandage, which is applied with a preloaded applicator and removed after a few minutes. Once applied, each patch delivers bioactive tips into the skin, which dissolve quickly into the body, rapidly releasing their therapeutic payload.

Designed for self-administration, the temperature-stable Tacterra™ platform enables precise, controlled delivery of a wide range of therapeutics without medical sharps or refrigeration. Terrestrial has generated strong clinical and in vivo proof of concept across multiple molecules.

Terrestrial Bio, Inc. is headquartered at 250 Western Avenue in Allston, with additional facilities at 30 Cummings Park Dr. and 11 Cummings Park Dr. in Woburn, MA.

Stay Ahead of the US Chemical Sector Growth, From Coast to Coast

Every year, billions of dollars in chemical infrastructure, production, and commercial projects flow through the pipeline in the United States, and the firms that succeed are the ones that identify the opportunities first. Whether you're monitoring a new plant development or a chemical processing expansion, timely intelligence makes all the difference.

The Global Power Tracking (GPT) platform from Blackridge Research provides you with a real-time view of project activity across the United States chemical sector. Rather than assembling news clippings and outdated databases, you gain access to a single, continuously updated source of truth for the entire project lifecycle.

From project inception to completion, the platform offers all critical advancements in the chemical sector at your fingertips, empowering your business development team to capitalize on opportunities well before competitors.

• Upcoming Projects

• Tender Notices

• Contract Awards

• Projects Under Construction

• Completed Projects

Ready to see how it works for your pipeline? Book a Free Demo of the Global Project Tracking (GPT) platform by Blackridge Research today.